Inhibition by protease inhibitors of binding of adrenal and sex steroid hormones
β Scribed by Baker, Michael E. ;Vaughn, Duke A. ;Fanestil, Darrell D.
- Publisher
- Wiley (John Wiley & Sons)
- Year
- 1978
- Tongue
- English
- Weight
- 329 KB
- Volume
- 9
- Category
- Article
- ISSN
- 0091-7419
No coin nor oath required. For personal study only.
β¦ Synopsis
Binding of steroid hormones is inhibited by protease inhibitors and substrates. The protease inhibitors phenylmethyl sulphonylfluoride, tosyl-lysine chloromethyl ketone, and tosylamide-phenylethyl-chloromethyl ketone and the protease substrates tosyl arginine methyl ester and tryptophan methyl ester eliminate specific binding of aldosterone, dexamethasone, dihydrotestosterone, estrogen, and progesterone to their respective receptors. These protease inhibitors and substrates also inhibit binding of progesterone t o the 20,000 molecular weight mero-receptor formed from the progesterone receptor in chick oviduct. The binding of estradiol t o rat alpha-fetoprotein is inhibited by the protease inhibitors and substrates but not by tryptophan or tryptophan amide, indicating the importance of an ester structure in the inhibition of steroid binding. Our results suggest that all steroid hormone receptors have a site with both common structural features and a role in the regulation of steroid hormone binding.
π SIMILAR VOLUMES
## Abstract Effects of protease inhibitors on development of mouse blastocysts and fibrinolytic activity of trophoblast were examined by growing embryos on monolayers of decidual cells in the presence of inhibitors. Nitrophenolβpβguanidino benzoate (NPGB) was the most effective inhibitor; 10^β4^ M
Testosterone, progesterone, and estradiol-17P each inhibit CAMP phosphodiesterase activity of mouse oocyte extracts in a concentrationdependent manner. This finding provides an explanation for the inhibitory effect of steroid hormones on germinal vesicle breakdown (GVBD) of mouse oocytes in vitro. F
## Abstract The absence of effective vaccines for most viral infections highlights an urgent necessity for the design and development of effective antiviral drugs. Due to the advancement in virology since the late 1980s, several key events in the viral life cycle have been well delineated and a num